Pipeline

An Innovation-Driven Company

Our rich pipeline of products, with seven approved NDAs in just seven years, demonstrates our leadership in developing technology-based drugs. Backed by decades of experience, we are able to streamline clinical development time and substantially increase the probability of late-stage product success.

TRN-124
Cough & Cold
 
Branded Pipeline Program: TRN-124
Indication: Cough & Cold
Commercial Partner: Vernalis
Approval: NDA Submission
TRN-110
ADHD in Pediatrics & Adults
 
Branded Pipeline Program: TRN-110
Indication: ADHD in Pediatrics & Adults
Commercial Partner: Tris
Approval: Advanced Clinical
TRN-123
Cough & Cold
 
Branded Pipeline Program: TRN-123
Indication: Cough & Cold
Commercial Partner: Vernalis
Approval: Early Clinical
TRN-112
Cough & Cold
 
Branded Pipeline Program: TRN-112
Indication: Cough & Cold
Commercial Partner: Vernalis
Approval: Early Clinical
TRN-148
Pediatric CNS
 
Branded Pipeline Program: TRN-148
Indication: Pediatric CNS
Commercial Partner: Tris
Approval: Early Clinical
TRN-146
Pediatric CNS
 
Branded Pipeline Program: TRN-146
Indication: Pediatric CNS
Commercial Partner: Undisclosed
Approval: Early Clinical
TRN-132
Pain
 
Branded Pipeline Program: TRN-132
Indication: Pain
Commercial Partner: Tris
Approval: Early Clinical
TRN-133
Urology
 
Branded Pipeline Program: TRN-133
Indication: Urology
Commercial Partner: Tris
Approval: Pre-Clinical
TRN-134
Sleep Disorder CNS
 
Branded Pipeline Program: TRN-134
Indication: Sleep Disorder CNS
Commercial Partner: Tris
Approval: Early Clinical
TRN-135
Pediatric CNS
 
Branded Pipeline Program: TRN-135
Indication: Pediatric CNS
Commercial Partner: Tris
Approval: Pre-Clinical